1. Home
  2. UBX vs NEPH Comparison

UBX vs NEPH Comparison

Compare UBX & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • NEPH
  • Stock Information
  • Founded
  • UBX 2009
  • NEPH 1997
  • Country
  • UBX United States
  • NEPH United States
  • Employees
  • UBX N/A
  • NEPH N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • NEPH Medical/Dental Instruments
  • Sector
  • UBX Health Care
  • NEPH Health Care
  • Exchange
  • UBX Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • UBX 20.4M
  • NEPH 16.8M
  • IPO Year
  • UBX 2018
  • NEPH 2004
  • Fundamental
  • Price
  • UBX $1.06
  • NEPH $2.03
  • Analyst Decision
  • UBX Strong Buy
  • NEPH Buy
  • Analyst Count
  • UBX 3
  • NEPH 1
  • Target Price
  • UBX $5.33
  • NEPH $5.00
  • AVG Volume (30 Days)
  • UBX 227.8K
  • NEPH 12.2K
  • Earning Date
  • UBX 05-13-2025
  • NEPH 05-08-2025
  • Dividend Yield
  • UBX N/A
  • NEPH N/A
  • EPS Growth
  • UBX N/A
  • NEPH N/A
  • EPS
  • UBX N/A
  • NEPH 0.01
  • Revenue
  • UBX N/A
  • NEPH $14,162,000.00
  • Revenue This Year
  • UBX N/A
  • NEPH $9.23
  • Revenue Next Year
  • UBX N/A
  • NEPH $12.99
  • P/E Ratio
  • UBX N/A
  • NEPH $290.01
  • Revenue Growth
  • UBX N/A
  • NEPH N/A
  • 52 Week Low
  • UBX $0.94
  • NEPH $1.36
  • 52 Week High
  • UBX $3.10
  • NEPH $2.55
  • Technical
  • Relative Strength Index (RSI)
  • UBX 31.85
  • NEPH 76.08
  • Support Level
  • UBX $1.16
  • NEPH $1.55
  • Resistance Level
  • UBX $1.22
  • NEPH $1.62
  • Average True Range (ATR)
  • UBX 0.13
  • NEPH 0.10
  • MACD
  • UBX -0.06
  • NEPH 0.04
  • Stochastic Oscillator
  • UBX 12.22
  • NEPH 98.18

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.

Share on Social Networks: